[Pharmaceutical development and clinical experiment of new antidiabetic drugs, premixed preparations of insulin lispro (Humalog Mix 25 and Humalog Mix 50) and intermediate-acting insulin lispro (Humalog N)]

Nihon Yakurigaku Zasshi. 2005 Aug;126(2):143-51. doi: 10.1254/fpj.126.143.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Biphasic Insulins
  • Drug Design
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / pharmacokinetics
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / administration & dosage
  • Insulin / analogs & derivatives*
  • Insulin / pharmacokinetics
  • Insulin / therapeutic use
  • Insulin Lispro
  • Insulin, Isophane
  • Quality of Life

Substances

  • Biphasic Insulins
  • Hypoglycemic Agents
  • Insulin
  • Insulin Lispro
  • insulin lispro, isophane insulin lispro drug combination (25:75)
  • isophane insulin, insulin lispro drug combination 50:50
  • Insulin, Isophane